CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentDavid A. Flockhart, Lü Li, A. Araba et al.|JNCI Journal of the National Cancer Institute|2005Cited by 947
Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast CancerN. Lynn Henry, Anna Maria Storniolo, Faouzi Azzouz et al.|Journal of Clinical Oncology|2012Cited by 391
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug ResponseKathleen M. Giacomini, Issam Zineh, Christopher M. A. Brett et al.|Clinical Pharmacology & Therapeutics|2007Cited by 243
Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer PatientsSilvana Borges, Lang Li, Zeruesenay Desta et al.|The Journal of Clinical Pharmacology|2010Cited by 128
Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and AgeZeruesenay Desta, David A. Flockhart, Yvonne Kreutz et al.|Clinical Pharmacology & Therapeutics|2011Cited by 108